Show simple item record

dc.creatorDe Meyer, Sandra
dc.creatorBojkova, Denisa
dc.creatorCinatl, Jindrich
dc.creatorVan Damme, Ellen
dc.creatorBuyck, Christophe
dc.creatorVan Loock, Marnix
dc.creatorWoodfal, Brian
dc.creatorCiesek, Sandra
dc.date.accessioned2020-07-17T17:19:07Z
dc.date.available2020-07-17T17:19:07Z
dc.date.created2020
dc.identifier.issn1201-9712spa
dc.identifier.otherhttps://doi.org/10.1016/j.ijid.2020.05.085spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10765
dc.description.abstractObjectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 mM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 mM). Conclusions: Overall, the data do not support the use of DRV for the treatment of COVID-19.spa
dc.format.extent4 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectDarunavirspa
dc.subjectSARS-CoV-2spa
dc.subjectCOVID-19spa
dc.subjectIn vitrospa
dc.titleLack of antiviral activity of darunavir against SARS-CoV-2spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2020.05.085spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record